SMMT FY2025 SEC EDGAR DEF 14A #162 of 168 in industry

Summit Therapeutics Inc. CEO pay ratio

The CEO earned $1.0M in FY2025 against median worker pay of $503,340 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
FL
Filing date
2026-04-17
Industry
Chemicals & Pharmaceuticals
Industry rank
#162/168

Data updated August 2026

Subscribe to Summit Therapeutics Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
3:1
Below Average (Scale: 0–1000:1)
CEO pay
$1.0M
Median worker
$503,340

Answer first

Summit Therapeutics Inc.'s FY2025 CEO total of $1.0M ranks #1228 of 1,423 complete filings; its 3:1 pay ratio ranks #1384. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $503,340. Industry placement uses the FY2025 SIC-28 peer cohort (# 162 of 168, 4th percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#1228
$1.0M of 1,423 FY2025
Ratio rank
#1384
3:1 of 1,423
Industry pct
4th
among the lower quartile of industry peers by pay ratio

How Summit Therapeutics Inc. ranks nationally

Summit Therapeutics Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$1,025,895 14th percentile higher than 14% of 1,423 companies

$0–$2,500,000: 304 companies (21%). This entry sits in this band. $2,500,000–$5,000,000: 182 companies (13%). Above this entry. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Summit Therapeutics Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($1.0M) against pay ratio (3:1) for Summit Therapeutics Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02069254.34138508.56207762.88277017.10:111:122:133:144:1CEO total payPay ratio (CEO : median worker)Summit Therapeutics Inc., CEO total pay: 1025895 · Pay ratio (CEO : median worker): 3:1Summit Therapeutics Inc.Vera Therapeutics, Inc., CEO total pay: 6986410 · Pay ratio (CEO : median worker): 3:1Vera Therapeutics, Inc.Highwater Ethanol LLC, CEO total pay: 394644 · Pay ratio (CEO : median worker): 4:1Highwater Ethanol LLCTwist Bioscience Corp, CEO total pay: 376416 · Pay ratio (CEO : median worker): 2:1Twist Bioscience CorpViridian Therapeutics, Inc.\DE, CEO total pay: 6776249 · Pay ratio (CEO : median worker): 4:1Viridian Therapeutics, Inc.\DERoyalty Pharma plc, CEO total pay: 349893 · Pay ratio (CEO : median worker): 4:1Royalty Pharma plc
Summit Therapeutics Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Summit Therapeutics Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
3:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$1.0M
Companies in Industry
168
vs. Industry Median
Below
#162 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Summit Therapeutics Inc.: near-parity Item 402(u) ratio

Summit Therapeutics Inc.'s FY2025 ratio 3:1 ranks #162 of 168 Chemicals & Pharmaceuticals filers (4th percentile). the CEO earned 3× the median employee ($503,340) in FY2025.

At $503,340 median worker pay, the FLOOR stamp is near pay-parity territory under LIGHT CEO total.

CEO Total Pay

$1.0M

FY2025 Summary Compensation, below median

Pay Ratio

3:1

Below typical

Summit Therapeutics Inc. in the lower Chemicals & Pharmaceuticals third

Summit Therapeutics Inc.'s FY2025 ratio 3:1 ranks #162 of 168 Chemicals & Pharmaceuticals filers (4th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Summit Therapeutics Inc.'s $1.0M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #1228 and ratio rank #1384 split - treat 3:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$1.0M
Median Employee Pay
$503,340
Pay Ratio
3:1
Filing Date
2026-04-17

Company Info

Ticker
SMMT
CIK
1599298
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
FL
View SEC filings →
SEC EDGAR DEF 14A for CIK 1599298, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Summit Therapeutics Inc.'s FY2025 ratio 3:1 ranks #162 of 168 Chemicals & Pharmaceuticals filers (4th percentile).

Read with Summit Therapeutics Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · LIGHT · ELITE-MED.

Republic Bancorp Inc /ky/ · LIGHT

ABS(ceo_total_comp) peer at $1.0M (Δ $2K lighter vs Summit Therapeutics Inc.); FLOOR · PAR-MED vs this page's FLOOR · LIGHT · ELITE-MED.
PJT Partners Inc. · LIGHT

ABS(ceo_total_comp) peer at $1.0M (Δ $5K heavier vs Summit Therapeutics Inc.); FLOOR · ELITE-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Urban Outfitters Inc · LIGHT

ABS(ceo_total_comp) peer at $1.0M (Δ $15K heavier vs Summit Therapeutics Inc.); MODEST · LOW-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Bancfirst Corp /ok/ · LIGHT

ABS(ceo_total_comp) peer at $1.0M (Δ $21K lighter vs Summit Therapeutics Inc.); FLOOR · PAR-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Vera Therapeutics, Inc. (SIC 28 pole)

Vera Therapeutics, Inc. stamps FLOOR · HEAVY nearest in-SIC by ABS(pay_ratio) to Summit Therapeutics Inc.'s FLOOR filing.
National dual ranks · #1228/#1384

Summit Therapeutics Inc.'s FY2025 package sits #1228 by CEO dollars and #1384 by ratio under LIGHT · FLOOR.
Ratio primer · FLOOR

Summit Therapeutics Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Summit Therapeutics Inc. (CIK 1599298), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.